Compare AbCellera Biologics Inc (ABCL) vs Firy Inc. (FIRY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Firy Inc. — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Firy Inc. trades at $9.3 (market cap $143.59M). The key difference: AbCellera Biologics Inc is far larger — about 16.4× Firy Inc.'s market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Firy Inc. nearer its low. Which is the better fit depends on your goals.
| ABCL | FIRY | |
|---|---|---|
Market Cap | $2.35B | $143.59M |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $12.45 |
52-Week Low | $2.78 | $2.28 |
Enterprise Value | $1.99B | $87.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
FIRY, formerly Skillz Inc., trades at $9.20, down 5.54% today, amid a recent rebranding and mixed quarterly results. The stock shows a bullish technical signal with strong moving average support, while fundamentals reveal persistent losses despite a high gross margin of 87.75%. Revenue has declined from $270M in 2022 to $104M in 2025, with net income margins deeply negative. Cash flow remains negative, though operating losses have narrowed from 2022 peaks.
Outlook is cautious; the company's cost structure and profitability challenges pose significant risks, offset by potential from legal victories and strategic shifts. Analysts are mostly neutral, with 60% hold ratings. Investors should weigh the high execution risk against any turnaround prospects in the competitive mobile gaming sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
